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n INTRODUCTION
Pseudomonas aeruginosa is known as a non-fer-menting Gram-negative bacillus that is mo-
tile, catalase- and oxidase-positive. P. aeruginosa 
is an opportunistic pathogen widely distributed 
in the hospital environments and accounts for 
severe diseases such as urinary tract infections 
(UTIs), bloodstream infections (BSIs), pneumo-
nia and wound infections, especially in immuno-
compromised patients [1]. Besides, P. aeruginosa is 
clinically important since it possesses several vir-
ulence factors that can cause serious health prob-
lems [2]. Treatment of P. aeruginosa infections is 
considered as a major problem for physician due 
to a wide variety of antibiotic resistance mecha-
nisms documented in this species, particularly 
production of extended-spectrum-beta-lactama-
ses (ESBL) and metallo-beta-lactamases (MBL) 
enzymes. The ESBL and MBL production enables 
bacteria to hydrolyze extended-spectrum cepha-
losporins and carbapenems, conferring resistance 
against ceftazidime, ceftriaxone, cefotaxime and 
carbapenems [3]. Four classes of beta-lactamase 
enzymes including class A, B, C and D have been 
recognized. Based on the molecular structure and 
protein homology, these classes are divided into 
different subclasses. Molecular study of class A 
(VEB, PER, GES, SHV, PSE, BEL and CTX-M, C 
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Metallo-beta-lactamase (MBL)-producing Pseudomonas 
aeruginosa is considered to be a serious threat to human 
health worldwide. Limited information is available 
concerning the prevalence of MBL-producing P. aerugi-
nosa in Iran. The aim of the present study was to inves-
tigate the prevalence of MBL-producing P. aeruginosa 
in different parts of Iran. We searched major electronic 
databases including PubMed, ISI Web of Science, Scop-
us and Google Scholar as well as two Iranian search 
engines using appropriate keywords. After applying 
inclusion and exclusion criteria, related papers were 
recruited for the study. The prevalence of MBL-pro-
ducing P. aeruginosa in Iranian population was about 
SUMMARY
32.4 percent. Our findings also revealed that the high-
est prevalence of MBL-producing P. aeruginosa was in 
Isfahan with 60% (95% CI: 0.27-0.86). In addition, in 
Iranian population the most reported MBL gene was 
blaVIM and blaIMP, with frequencies of 19% (95% CI: 
0.15-0.23) and 11% (95% CI: 0.08-0.14), respectively. 
Based on our findings, in the majority of Iranian hospi-
tals, the prevalence of MBL-producing P. aeruginosa is 
alarmingly high necessitating the need for designing 
appropriate infection control programs. 
Keywords: Metallo-beta-lactamase, Pseudomonas aerugi- 
nosa, Imipenem resistance.
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(AmpC) and D (OXA-type-enzymes) revealed 
that these enzymes use a catalytically active serine 
residue for the inactivation of beta-lactam antibi-
otics, whereas class B beta-lactamases (IMP, VIM, 
GIM, SPM, NDM) are metallo-beta-lactamases 
and require zinc [4, 5]. Apart from simultaneous 
resistance against different antibiotics, the most 
important feature of multi-drug resistant strains 
is that these isolates have developed a wide ar-
ray of strategies to evade the killing activity of the 
antibiotics, including the horizontal gene transfer 
among species [6].
Determination of the prevalence of MBL-produc-
ing isolates is crucial to guide infection control 
policies and appropriate use of antibiotics; there-
fore, the aim of the present study was to inves-
tigate the relative frequency (RF) of MBL-pro-
ducing P. aeruginosa in different parts of Iran. To 
this end, we performed a systematic literature 
review to find published data on the prevalence 
of MBL-producing P. aeruginosa in different prov-
inces of Iran.
n MATERIALS AND METHODS
Search strategy
We searched major electronic databases includ-
ing PubMed, ISI Web of Science, Scopus and 
Google Scholar, as well as two Iranian search 
engines including Iranian Scientific Information 
(www.sid.ir) and Magiran (www.magiran.com). 
In addition, citations of articles were manually 
searched to find relevant missing articles. Fol-
lowing keywords in combination were used; 
“Pseudomonas aeruginosa” AND “Iran” AND/
OR “MBL-producing P. aeruginosa” AND “Iran” 
AND/OR “multi-drug resistance P. aeruginosa” 
AND “Iran”. Our study was restricted to the 
original articles/brief reports published in Per-
sian or English and reporting the prevalence of 
MBL-producing P. aeruginosa by phenotypic and 
molecular (PCR) methods.
Inclusion criteria
Inclusion criteria used in the present study were 
as follows:
– P. aeruginosa isolates were collected from pa-
tients referred to Iranian hospitals. 
– P. aeruginosa strains were collected from clini-
cal samples. 
– Phenotypic methods (imipenem/meropenem 
alone, and in combination with EDTA) ac-
cording to CLSI guidelines were used to detect 
prevalence of MBL-producing isolates of P. 
aeruginosa, because these are approved meth-
ods and are widely available.
– Cross-sectional descriptive studies (analyzed 
data from a population).
Exclusion criteria
Articles were excluded if:
– Samples were partially or totally taken from 
archive of antibiotic-resistant strains of P. 
aeruginosa.
– Samples were collected from different parts of 
Iran, and we were unable to attribute findings 
to distinct provinces.
– Studies in which repetitive samples were used. 
– Studies with unclear materials and methods re-
garding the origin of samples, duplicate publi-
cations, and studies with incomplete results.
Data collection
According to defined criteria, data were collected 
and cross-checked based on titles, abstracts and 
full texts. Relative frequency of MBL-producing P. 
aeruginosa, name of the first author, time of study, 
and reported MBL resistance genes were extract-
ed from studies. Disagreements were resolved by 
discussion between the authors.
Statistical analysis
Total number of participants and the number of 
samples with MBL-producing P. aeruginosa were 
used to calculate logit event rate and its confidence 
interval to be used for meta-analysis [7]. The DerSi-
monial and Laird random-effects model was used 
to derive the summary estimate. The I-squared and 
Cochran’s Q test were used to assess heterogeneity 
between studies [7]. We used subgroup analysis to 
explore the prevalence rates according to province 
in which the study was conducted. 
To explore the extent to which the overall calcu-
lations might depend on a specific study, sensi-
tivity analysis was done. Publication bias was 
evaluated by inspecting Begg’s funnel plots and 
asymmetry tests including Egger’s regression 
asymmetry test and Begg’s adjusted rank cor-
relation test [7]. Statistical analyses were per-
formed using the Comprehensive Meta-analysis 
software (Version 2.2).
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Quality assessment
We used Joanna Briggs Institute (JBI) checklist 
to evaluate the quality of obtained papers [8]. 
According to this checklist several items such as 
population size, research objectives, sample col-
lection method and statistical analysis approach 
are evaluated. One score was assigned to each pa-
rameter and study was included if at least seven 
scores achieved.
n RESULTS
Totally, we found 2,552 records by applying the 
aforementioned search strategies (Figure 1). After 
title and abstract screening and evaluation, 1800 
articles were excluded. Ultimately, based on ap-
plied exclusion criteria, 26 articles with full text 
describing the prevalence of MBL-producing P. 
aeruginosa were selected for this systematic re-
view and meta-analysis (Table 1) [9-34]. 
Most of studies were performed in Tehran (7) and 
Isfahan (4), followed by Ahvaz (3), Shiraz (3), Ker-
manshah (2), Mashhad (2), Zanjan (2), Zahedan 
(1), Markazi (1) and Urmia (1). Based on our find-
ings, the prevalence of MBL-producing P. aerug-
inosa in the Iranian population was about 32.4% 
(95% CI: 24.4-41.5) (Figure 2). The heterogeneity 
between studies was significant (Cochran’s Q test, 
Q statistic = 517.036, P value<0.001, I2=95.16%). 
Although a slight asymmetry was seen in the fun-
nel plot (Figure 3), asymmetry tests did not show 
Figure 1 - Flow diagram show-
ing literature review progress 
All’interno della figura, elimi-
narne il titolo.
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any evidence of publication bias (Begg’s test, P 
value=0.208, Egger’s test, P value=0.338). 
Our findings also revealed that the highest prev-
alence of MBL-producing P. aeruginosa was in Is-
fahan (60%, 95% CI: 0.27-0.86), while the lowest 
prevalence was reported from Zahedan province 
(4.7%, 95% CI: 0.02-0.08) (Table 1). In addition, in 
Iranian population the most frequently reported 
Table 1 - Characteristics of studies involved in the systematic review and meta-analysis
Abbreviation: W, wound; B, blood culture; U, urinary tract infection; Sp, sputum; BW, burn wound; CDDT, combined double disk test.
First author
Time of 
study
Province
Total 
samples
Type of 
samples
Laboratory method
MBL proportion 
(%)
Ref.
Khosravi 2005-006 Ahvaz 100 W, B, U Etest, PCR 8 23
Mosavian 2011-012 Ahvaz 236 W, B, U, Sp CDDT, PCR 46.6 26
Sheikh 2011-2012 Ahvaz 223 W, B, U, Sp CDDT, PCR 45.7 15
Total 30.6
Rastegar 2013 Tehran 255 BW CDDT, PCR 0 24
Fallah 2012 Tehran 100 BW CDDT, PCR 48 14
Saderi 2008 Tehran 100 BW CDDT, PCR 65 30
Hakemivala 2012 Tehran 47 BW CDDT, PCR 27.7 18
Aghamiri 2011-012 Tehran 212 W, B, U, Sp CDDT, PCR 33 10
Bejestani 2011-012 Tehran 90 W, B, U, Sp CDDT, PCR 3.3 12
Sadredinamin 2014-015 Tehran 100 BW CDDT, PCR 81 31
Total 31.2
Doosti 2011-012 Zanjan 70 W, B, U, Sp CDDT, PCR 51.4 13
Hemati 2012-013 Zanjan 120 W, B, U, Sp CDDT, PCR 29.2 19
Total 39.6
Sarhangi 2011-012 Shiraz 240 W, B, U, Sp CDDT, PCR 7.9 33
Japoni 2009-010 Shiraz 270 BW Etest 22.2 20
Rostampour 2012-013 Shiraz 42 BW CDDT, PCR 61.9 28
Total 25.1
Fazeli 2008-009 Isfahan 79 BW CDDT, PCR 51.9 16
Khorvash 2012-013 Isfahan 48 W, B, U, Sp CDDT, PCR 43.8 22
Saffari 2014-015 Isfahan 150 BW CDDT, PCR 96 32
Sedighi 2012-013 Isfahan 106 W, B, U, Sp CDDT, PCR 24.5 34
Total 60.7
Nakhaei 2014 Mashhad 70 W, B, U, Sp CDDT, PCR 35.7 27
Mirbagheri 2011-012 Mashhad 131 W, B, U, Sp CDDT, PCR 49.6 25
Total 43.2
Akya 2011-012 Kermanshah 60 W, B, U, Sp CDDT, PCR 48.3 11
Abiri 2012 Kermanshah 225 W, B, U, Sp CDDT, PCR 20 9
Total 32.3
Ghamgosha 2012-013 Zahedan 191 U, Sp, W Etest, PCR 4.7 17
Jazani 2010 Urmia 100 W, B, U, Sp CDDT 7 21
Sadeghi 2011-012 Markazi 108 W, B, U, Sp CDDT, PCR 18.5 29
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Figure 2 - Meta-anal-
ysis examining the 
overall prevalence 
of MBL-producing P. 
aeruginosa on stud-
ies conducted in Iran. 
The analysis revealed 
that the overall preva-
lence was about 32.4% 
(95%CI: 24.4-41.5). The 
analysis was conduct-
ed using random-ef-
fects model. 
Figure 3 - Funnel plot with pseudo 95% confidence interval demonstrating the effect sizes derived from each 
study (logit event rate) against their corresponding standard errors (SEs). 
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MBL genes were blaVIM and blaIMP, with 19% 
(95% CI: 0.15-0.23) and 11% (95% CI: 0.08-0.14), 
respectively (Table 2). The highest prevalence 
rates of blaVIM and blaIMP were seen in Mash-
had (50%, 95% CI: 0.41-0.58) and Isfahan (31.3%, 
95%CI: 0.15-0.37), respectively.
n DISCUSSION
The importance of P. aeruginosa in causing infec-
tions in the Iranian hospitals has been particu-
larly highlighted in recent years and antibiotic 
resistance rates against this microorganism have 
been reported from different parts of the country. 
We conducted this study to provide a systematic 
evaluation of the prevalence of MBL-producing P. 
aeruginosa in Iran. 
In this study, we collected data on the prevalence 
of MBL-producing P. aeruginosa in hospitals 
of different cities of Iran. Several independent 
studies have reported the substantial impact of 
MBL-producing P. aeruginosa on patients’ out-
comes [35-37]. For example, the study conduct-
ed by Lautenbach et al. revealed that carbapen-
em-resistant P. aeruginosa strains are associated 
with a high mortality rate and hospitalization 
[35]. A study conducted in three German hospi-
tals also showed that the mortality rate is signifi-
cantly higher in patients infected with MBL-pro-
Table 2 - Prevalence of MBL-genes based on different provinces.
Abbreviation; NA, not applicable.
First author Province (Ref.)
MBL-genes (proportion %)
VIM IMP SPM KHM SIM
Khosravi Ahvaz (23) 8 0.5 NA NA NA
Sheikh Ahvaz (15) 0.4 11.7 0 NA NA
Mosavian Ahvaz (26) 0.8 28.4 0 NA NA
Rastegar Tehran (24) 2 1.6 0 NA NA
Saderi Tehran (30) 13 0.5 NA NA NA
Aghamiri Tehran (10) 33 9.4 NA NA NA
Fallah Tehran (14) 0.5 6 NA NA NA
Hakemivala Tehran (18) 0.1 2.1 0 NA NA
Bejestani Tehran (12) 0.5 3.3 NA NA NA
Sadredin Tehran (31) 0 13 NA NA NA
Hemati Zanjan (19) NA 23.3 16.7 NA 4.2
Doosti Zanjan (13) 32 14.3 NA NA NA
Saffari Isfahan (32) 21 NA NA NA NA
Fazeli Isfahan (16) 43 NA NA NA NA
Sedighi Isfahan (34) 0.5 NA NA NA NA
Khorvash Isfahan (22) 14.6 31.3 0 NA NA
Sadeghi Markazi (29) 38 2.8 0 NA NA
Ghamgosha Zahedan (17) 3.7 0.3 0 NA NA
Nakhaei Mashhad (27) 11.4 NA NA NA NA
Mirbagheri Mashhad (25) 50 NA NA NA NA
Akya Kermanshah (11) 8.3 NA NA NA NA
Abiri Kermanshah (9) 0.9 15.1 NA NA NA
Sarhangi Shiraz (33) 4.2 3.3 0 NA 0
Rostampou Shiraz (28) NA 11.9 0 9.5 NA
222 H. Vaez, F. Khademi, A. Salehi-Abargouei, et al.
ducing P. aeruginosa [37]. The present analysis 
revealed that the prevalence of MBL-producing 
P. aeruginosa in Iranian hospitals is alarming-
ly high, with an overall estimated prevalence 
of 32.4%. This prevalence is particularly high-
er than those reported from Swedish hospitals. 
For instance, the study by Erlandsson et al. in 
Swedish ICUs demonstrated that the prevalence 
of MBL-producing P. aeruginosa was less than 
1% [38]. The results of study conducted by Li-
akopoulos et al. in Greece showed that 28% of 
investigated isolates were MBL-producing [39]. 
Another study performed in 23 Korean hospitals 
during 2005 revealed that 10.8% of investigated 
P. aeruginosa isolates were MBL-producing [40]. 
Nevertheless, our findings indicate a lower prev-
alence compared with some regional countries; 
for example, the results of investigation conduct-
ed by Kaleem et al. in Pakistan showed that the 
prevalence of MBL-producing P. aeruginosa was 
78% [41]. Also, Hashem et al. demonstrated that 
the prevalence of MBL-producing P. aeruginosa 
was 64% in Egypt [42]. According to our find-
ings extracted from 26 articles, the prevalence of 
MBL-producing P. aeruginosa was 32.4% and was 
more than 30% in many Iranian cities (Table 1). 
With a provincial perspective, our meta-analy-
sis suggested that Isfahan had the highest prev-
alence (60%), followed by Mashhad (43%). The 
lowest prevalence of resistance was reported 
from Zahedan (4.7%) (Table 1).
Diversity in the prevalence of MBL-producing 
P. aeruginosa in different regions is attributable 
to irregular and varied use of antibiotics, low 
quality of personal hygiene, and inadequate en-
vironmental cleaning and infection control pol-
icies [43]. According to our findings, blaVIM is 
the most widely investigated gene in P. aerugino-
sa strains isolated from patients admitted to Ira-
nian hospitals (reported in 22 studies) followed 
by IMP (reported in 18 studies) (Table 2). The 
highest reported prevalences for blaVIM, and 
blaIMP genes were 19% (95% CI: 0.15-0.23) and 
11% (95% CI: 0.08-0.14), respectively. The high-
est prevalence of these genes was reported from 
Mashhad (50% for blaVIM) and Isfahan (31.3% 
for blaIMP).
Verona integron-encoded metallo-β-lactamases 
(VIM) are one of the most important beta- lacta-
mases identified in P. aeruginosa. VIM-producing 
isolates of P. aeruginosa have been reported world-
wide, including in European countries such as It-
aly, France, Greece, Belgium, Germany, Sweden, 
and some countries of Asia such as Japan, South 
Korea and Malaysia [44-51]. 
MBL genes are usually located in transferable 
genetic elements such as integrons and plas-
mids along with other antibiotic resistance genes. 
Therefore, dissemination of strains harboring 
MBL genes are of crucial importance, and appro-
priate measures should be taken into considera-
tion by infection control programs [52].
KHM and SIM are novel MBLs which were first 
identified in Citrobacter freundii isolated from pa-
tients with urinary tract infection in Japan and 
from Acinetobacter baumannii isolated from pa-
tients with urinary tract infection in Korea, re-
spectively [53, 54]. Noteworthy, these novel MBL 
enzymes have been reported from Shiraz and 
Zanjan provinces by Rostampour et al. and He-
mati et al., indicating rapid dissemination of MBL 
genes [19, 28].
It has been documented that implementation of 
rational antibiotic use guidelines is integral to 
prevent dissemination of antibiotic resistance 
strains. Adequate dosing regimen according to 
pharmacokinetics-pharmacodynamics parame-
ters and renal function, avoidance of arbitrary an-
tibiotic administration, use of definitive regimens 
instead of empirical therapy when results of an-
tibiotic susceptibility tests are available and ad-
equate documentation of administration are key 
elements to achieve a proper pattern of antibiotic 
use [55, 56].
There are some limitations that should be taken 
into account while interpreting the results of the 
present meta-analysis. The results obtained by 
phenotypic and genotypic methods may not be 
the same due to different specificity and sensivity 
values of applied methods. Moreover, data was 
not available from all regions of Iran; thus, our 
findings cannot fully represent the prevalence of 
MBL-producing P. aeruginosa in Iran.
n CONCLUSION
Based on the present findings, the prevalence of 
MBL-producing P. aeruginosa is alarmingly high 
in the majority of Iranian hospitals. This should 
be considered as a serious threat to healthcare 
settings. Constant monitoring of MBL-producing 
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P. aeruginosa could guide antibiotic therapy and 
improve the patients’ outcomes, including hospi-
talization, mortality and morbidity.
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